Adverse Events in Patients Receiving Placebo in Phase III Trials of Biologics for Psoriasis: A Systematic Review and Meta-Analysis.

Gayathri Devaraj AjenthenAlexander EgebergKatrine Elsner MelgaardNikolai Dyrberg Loft

Published in: Journal of psoriasis and psoriatic arthritis (2022)

About half of the patients with moderate-to-severe psoriasis not starting an active treatment would experience disease events that would be categorized as AEs during a 12-16 weeks period.

Keyphrases

phase iii
open label
clinical trial
double blind
placebo controlled
early onset
atopic dermatitis
high intensity
randomized controlled trial
drug induced
preterm birth
study protocol